JBPH.F Stock Overview
An investment holding company, engages in the in-house discovery and development of oncology therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Jacobio Pharmaceuticals Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.29 |
| 52 Week High | HK$0.54 |
| 52 Week Low | HK$0.29 |
| Beta | 0.56 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -78.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| JBPH.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.6% | -0.5% |
| 1Y | n/a | -3.8% | 24.3% |
Return vs Industry: Insufficient data to determine how JBPH.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how JBPH.F performed against the US Market.
Price Volatility
| JBPH.F volatility | |
|---|---|
| JBPH.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: JBPH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine JBPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 301 | Yinxiang Wang | www.jacobiopharma.com |
Jacobio Pharmaceuticals Group Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company’s lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-(L)1 resistant cancer; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations.
Jacobio Pharmaceuticals Group Co., Ltd. Fundamentals Summary
| JBPH.F fundamental statistics | |
|---|---|
| Market cap | US$189.75m |
| Earnings (TTM) | -US$49.71m |
| Revenue (TTM) | US$8.79m |
21.6x
P/S Ratio-3.8x
P/E RatioIs JBPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JBPH.F income statement (TTM) | |
|---|---|
| Revenue | CN¥63.52m |
| Cost of Revenue | CN¥60.32m |
| Gross Profit | CN¥3.20m |
| Other Expenses | CN¥362.32m |
| Earnings | -CN¥359.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | 5.04% |
| Net Profit Margin | -565.36% |
| Debt/Equity Ratio | 6.9% |
How did JBPH.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/19 23:23 |
| End of Day Share Price | 2024/02/20 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jacobio Pharmaceuticals Group Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyi Chen | Goldman Sachs |